MDVX MEDOVEX CORP

Medovex Corporation Announces Name Change and Full Rebranding to Blue Zone Health

Medovex Corporation Announces Name Change and Full Rebranding to Blue Zone Health

New Company Identity Expands Focus to Deliver Innovative Health Care Solutions Around the World

ALPHARETTA, Ga., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”) today announced it is now Blue Zone Health. The announcement signals the company's broader commitment to bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases.

Blue Zone Health adopts its name from the “Blue Zones,” research spearheaded by Dan Buettner, showing the key to longevity lies in a holistic, daily approach to wellness. It identified five hotspots around the world where people on average are the healthiest and are living the longest, attributed to a diet of fresh foods, an active lifestyle, and a strong sense of community. Following this model, Blue Zone Health will operate at the intersection of science and wellness, bringing the latest medical solutions to people who want a better quality of life.

Blue Zone Health CEO William “Bill” Horne stated, “2019 has already been a critical year for our organization. Over the last couple of months, we have announced the successful asset purchase of , appointed trusted industry veterans to our board of directors, and secured the financing to continue to execute our business plan moving forward. Today’s announcement of the strategic rebranding to Blue Zone Health is another important step as our organization continues to evolve and represents a significant broadening of our focus while holding true to the original vision.”

Horne continued, “Together, the Blue Zone Health team intends to forge a unique combination of medical innovation and wellness expertise that is the future of health care. As traditional health care limitations are continually overcome with medical breakthroughs, Blue Zone Health aims to make those solutions accessible to all patients, especially those who seek the latest in available treatments for chronic conditions that hinder their quality of life.”

Current Blue Zone Health brands include the Lung Health Institute and DenerveX® System, and the company intends to continue to expand its portfolio in the near future to include more options for patients seeking the most innovative procedures and highest quality of medical care.

The Lung Health Institute is a leader in regenerative medicine, specializing in cellular therapy and complementary wellness programs that can help chronic lung disease patients improve their quality of life and lung function.

The DenerveX System is designed as a non-drug alternative to help people with facet joint syndrome get back to an active lifestyle.  During a minimally invasive procedure, the device is used to target and disrupt pain signals and receptors. Before this option, patients with facet joint disease often went through lengthy, expensive, and often ineffective conservative care options. The DenerveX Device is CE marked, but not currently FDA cleared. 

In addition to the name and anticipated symbol change, the Company will launch a new corporate website and social channels to provide educational resources for patients. The name change and an accompanying ticker symbol remain subject to the approval of the Financial Industry Regulatory Authority (FINRA).

About Blue Zone Health

Blue Zone Health is focused on delivering innovative technology and medical solutions that improve quality of life, especially for those with chronic disease. The company currently owns and manages the Lung Health Institute and DenerveX® System, and its board of directors continually seeks to bring new health care solutions to market domestically and internationally.  Inspired by the "Blue Zones" — five hotspots around the world where people on average are the healthiest and living the longest due to healthy diet, regular physical activity and strong sense of community – Blue Zone Health’s mission is to help people take a integrative approach to health and wellness. Its health solutions aim to help people prevent and decrease the effects of inflammation, often connected to chronic health conditions. For more information about Blue Zone Health, please visit .

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend," or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation, those outlined in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Contact Information

Blue Zone Health

Jason Assad

678-570-6791

EN
04/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MEDOVEX CORP

 PRESS RELEASE

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise Proceeds to Support Inorganic Growth and General Working Capital Purposes TAMPA, Fla., March 04, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that it has received $1,053,605 from the exercise of 75,257,511 previously issued warrants. The funds received will be used to fund the Company’s transition to a hybrid-biopharmaceutical company through strategic acquisitions, as well as for general working capital purposes. In connection with the exercise, the holders received f...

 PRESS RELEASE

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precis...

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc. Targets one of Healthcare’s Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology TAMPA, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that it has entered into a letter of intent for the acquisition of Catheter Precision, Inc. Catheter Precision is a medical device company focused on one of healthcare’s largest multi-billion dollar markets: Cardiac Electrophysiology. Catheter Precision has developed two cost-effective, user frie...

 PRESS RELEASE

H-CYTE Names Michael Yurkowsky Chief Executive Officer

H-CYTE Names Michael Yurkowsky Chief Executive Officer TAMPA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced that it has named Michael Yurkowsky as its Chief Executive Officer effective immediately. Michael Yurkowsky brings more than 25 years of experience in financial services to H-CYTE. He currently has served on the Company’s board of directors since 2019. He also serves as President and Chairman of Deverra Therapeutics, a clinical stage biotech developing allogeneic cel...

 PRESS RELEASE

H-CYTE Combines Clinical Outcomes and Scientific Development to Launch...

H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health Name change reflects investment in, and emphasis on, data-driven, patient-centric care relating to the company’s innovative PRP-PBMC treatment for chronic lung disorders. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’. Effec...

 PRESS RELEASE

H-CYTE Announces Publication of Additional Data that Further Supports ...

H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health Study Successfully Met Goal of Statistically Significant Improvement in Pulmonary Function at 3 Months Post-Treatment TAMPA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced the publication of new data supporting the safety and efficacy of its innovative autologous treatment in helping improve overall lung health. Pu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch